These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37019745)

  • 61. Impact of highly effective CFTR modulator therapy on digital clubbing in patients with cystic fibrosis.
    Mahlen T; Barton L; Roberts D
    J Cyst Fibros; 2022 Sep; 21(5):861-865. PubMed ID: 35915048
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis.
    Douglas JE; Civantos AM; Locke TB; Sweis AM; Hadjiliadis D; Hong G; Dorgan DJ; Kohanski MA; Palmer JN; Adappa ND
    Int Forum Allergy Rhinol; 2021 Feb; 11(2):201-203. PubMed ID: 33070454
    [No Abstract]   [Full Text] [Related]  

  • 63. Discovery heralds new approach to the treatment of cystic fibrosis.
    Lowe JA
    J Med Chem; 2014 Dec; 57(23):9774-5. PubMed ID: 25384240
    [No Abstract]   [Full Text] [Related]  

  • 64. After the Celebrations: Lessons from the New Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy.
    Barry PJ; Jones AM
    Ann Am Thorac Soc; 2019 Feb; 16(2):189-190. PubMed ID: 30707058
    [No Abstract]   [Full Text] [Related]  

  • 65. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy.
    Lahiri T; Sullivan JS
    Pediatr Pulmonol; 2022 Feb; 57 Suppl 1():S60-S74. PubMed ID: 34473419
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A new era in the treatment of cystic fibrosis.
    Lane MA; Doe SJ
    Clin Med (Lond); 2014 Feb; 14(1):76-8. PubMed ID: 24532752
    [No Abstract]   [Full Text] [Related]  

  • 67. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 69.
    Yeh HI; Hwang TC
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 35210304
    [No Abstract]   [Full Text] [Related]  

  • 70. Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?
    Merrill TB; Tyes J; Woodard TD
    Laryngoscope; 2024 Feb; 134(2):501-503. PubMed ID: 37548273
    [No Abstract]   [Full Text] [Related]  

  • 71. Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review.
    De la Hoz D; Villamil Osorio M; Restrepo-Gualteros SM
    Arch Argent Pediatr; 2019 Apr; 117(2):e131-e136. PubMed ID: 30869491
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Excitement mounts for first disease-modifying cystic fibrosis drugs.
    Opar A
    Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
    [No Abstract]   [Full Text] [Related]  

  • 73. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
    [No Abstract]   [Full Text] [Related]  

  • 74. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
    Egan ME
    Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 76. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.
    Middleton PG; Taylor-Cousar JL
    Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928
    [No Abstract]   [Full Text] [Related]  

  • 78. Promising new era dawns for cystic fibrosis treatment.
    Corbyn Z
    Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244
    [No Abstract]   [Full Text] [Related]  

  • 79. The march towards CFTR modulator access for all people with CF: The end of the beginning.
    VanDevanter DR
    J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
    [No Abstract]   [Full Text] [Related]  

  • 80. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
    Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
    Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.